Krystal Biotech Inc (KRYS)
80.21
-0.37 (-0.46%)
USD |
NASDAQ |
Feb 03, 16:00
80.16
-0.05 (-0.06%)
After-Hours: 19:59
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 2.065B |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | 44.78% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | -- |
| Price to Book Value | 3.819 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | -- |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 53.42% |
News
Headline
Wire
Time (ET)
MT Newswires
01/18 07:30
Globe Newswire
01/18 07:00
SA Breaking News
01/10 04:57
Yahoo
01/09 15:34
Globe Newswire
01/09 08:00
Yahoo
01/09 08:00
Events
| DATE | TIME | TYPE | PERIOD | REPORTED EPS |
ESTIMATED EPS |
SURPRISE | |
| 02/28/2023* | -- | Results | Q4 2022 | -- | -0.83 | -- | |
| 11/07/2022 | -- | Results | Q3 2022 | -1.17 | -1.26 | 6.96% | |
| 08/08/2022 | -- | Results | Q2 2022 | -1.10 | -1.00 | -9.63% | |
| 05/09/2022 | -- | Results | Q1 2022 | -0.99 | -1.06 | 6.23% | |
| 02/28/2022 | -- | Results | Q4 2021 | -0.95 | -0.73 | -29.69% | |
| 11/08/2021 | -- | Results | Q3 2021 | -0.70 | -0.74 | 5.22% | |
| 08/09/2021 | -- | Results | Q2 2021 | -0.74 | -0.78 | 4.92% | |
| 05/10/2021 | -- | Results | Q1 2021 | -0.74 | -0.56 | -32.14% |
*Estimated Date/Time
Earnings
Profile
Edit
| Krystal Biotech Inc is engaged in the healthcare sector in the United States. It is focused on development of easy to use, redosable gene therapies to improve the lives of patients living with debilitating diseases. The company used its proprietary gene therapy platform, STAR-D to develop treatments for rare or orphan dermatological indications caused by the absence of or a mutation in a single gene. It plans to leverage its platform to expand its pipeline to include other dermatological indications in the future. |
| URL | https://www.krystalbio.com |
| Investor Relations URL | https://ir.krystalbio.com/ |
| HQ State/Province | Pennsylvania |
| Sector | Healthcare |
| Industry | Biotechnology |
| Equity Style | Small Cap/Blend |
| Next Earnings Release | Feb. 28, 2023 (est.) |
| Last Earnings Release | Nov. 07, 2022 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Analyst Coverage
|
Consensus Rating
|
|
|
Analyst Recommendation
|
|
Source: S&P Global
Dividends
| Dividend Per Share (TTM) | -- |
|
2017
2018
2019
2020
2021
6.00%
4.00%
2.00%
|
|
| Yield to Market | 0.00 |
| Yield to Sector | 0.00 |
| Yield to Industry | 0.00 |
| Last Dividend Amt. | -- |
| Dividend Frequency | -- |
| Last Ex-Dividend Date | -- |
| Yield (TTM) | 0.00% |
| Forward Yield | -- |
| Payout Ratio | -- |
| Cash Payout Ratio | -- |
| Consistent Payer (5Y) | No |
| Consistent Growth (5Y) | No |
Risk Info
Total Returns Comparison
Annual Total Returns Versus Peers
As of February 03, 2023.
Fundamentals
2017
2018
2019
2020
2021
4.00
2.00
1.00
| Revenue (TTM) | -- |
| Total Expenses (TTM) | 107.30M |
| Net Income (TTM) | -129.73M |
| Total Assets (Quarterly) | 576.38M |
| Total Liabilities (Quarterly) | 35.61M |
| Shareholders Equity (Quarterly) | 540.77M |
| Cash from Operations (TTM) | -99.14M |
| Cash from Investing (TTM) | -235.42M |
| Cash from Financing (TTM) | 234.35M |
Ratings
Profile
Edit
| Krystal Biotech Inc is engaged in the healthcare sector in the United States. It is focused on development of easy to use, redosable gene therapies to improve the lives of patients living with debilitating diseases. The company used its proprietary gene therapy platform, STAR-D to develop treatments for rare or orphan dermatological indications caused by the absence of or a mutation in a single gene. It plans to leverage its platform to expand its pipeline to include other dermatological indications in the future. |
| URL | https://www.krystalbio.com |
| Investor Relations URL | https://ir.krystalbio.com/ |
| HQ State/Province | Pennsylvania |
| Sector | Healthcare |
| Industry | Biotechnology |
| Equity Style | Small Cap/Blend |
| Next Earnings Release | Feb. 28, 2023 (est.) |
| Last Earnings Release | Nov. 07, 2022 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Risk Info
Ownership
| Insider Ownership Percentage | Upgrade |
Jul '20
Nov '20
Mar '21
80.00%
40.00%
10.00%
Analyst Coverage
|
Consensus Rating
|
|
|
Analyst Recommendation
|
|
Source: S&P Global
Other Resources
| Whale Wisdom | 13F Filings |
| Seeking Alpha | Call Transcripts |
| Nasdaq | Insider Trading |
| Nasdaq | Institutional Ownership |
| Nasdaq | Option Chain |
| SEC | SEC Filings |
| KRYS Tweets |